ReviewMaterials today. Bio2025
Peptide hydrogel-drug conjugates for tailored disease treatment.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A targeted triple-action redox-modulating hydrogel potentiates fibroblast-mediated repair to accelerate oral wound healing.Materials today. Bio · 2026Article
- Antibacterial and Wound-Healing Efficacy of 12-Hydroxylauric Acid-Conjugated Heterochiral Diphenylalanines: Insights From In Vitro and In Vivo Investigations.Chembiochem : a European journal of chemical biology · 2026Article
- Fundamentals and Advances in Programmable Peptide Hydrogels for Multifunctional Biomedical Applications: A Review.Gels (Basel, Switzerland) · 2026Review
- Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.Materials today. Bio · 2025Review
- Biological Models for Evaluating Hydrogel-Based Formulations in Wound Healing.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficacy of therapeutic drugs is oftentimes limited in time by their low metabolic stability and rapid clearance mechanisms. Peptide hydrogels have been used for the physical encapsulation of a vast number of drugs in the treatment of many different disease states, thereby effectively prolonging activity profiles of these drugs. However, consistent drug loading and release is generally lacking, while the delivery of hydrophobic drugs remains problematic. Many of these shortcomings can be addressed by covalently attaching the drug to the hydrogelator, thereby creating hydrogel-drug conjugates. Their easy synthesis and functionalization, alongside their biocompatibility, makes peptide hydrogels particularly fit for this purpose. Release can readily be tuned depending on the choice of linker connecting the drug to the hydrogelator, where it can be specifically directed towards the site of action, which limits undesired side effects. By attaching appropriate targeting motifs, additional site-selectivity can be obtained. This review provides an overview of the main principles applied in the development of peptide-based hydrogel-drug conjugates, illustrated with a selection of representative examples from literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.